Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Thoracic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Neoplasms 3Brain Neoplasms 3Meningeal Carcinomatosis 1Glioblastoma 1Breast Neoplasms 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × XL647 × Clear all
NCT00086528 2022-05-13

Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors

Kadmon Corporation, LLC

Phase 1 Completed
41 enrolled
Tumor-Agnostic

Neoplasms

NCT00336765 2022-05-13

Study of XL647 Administered Orally Daily to Patients With Solid Tumors

Kadmon Corporation, LLC

Phase 1 Completed
31 enrolled
Tumor-Agnostic

Neoplasms

NCT00704392 2015-08-20

Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors

Exelixis

Phase 1 Withdrawn
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡